Dr. Reddy's Laboratories
- Market cap
- 10.22B
- P/E (TTM)i
- 29.93
- P/Bi
- 2.58
- EPSi
- 0.53
- Div yieldi
- 0.69%
- 52W posi
- 23%
Anonymous reader poll. Unscientific, not investment advice.
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment refers to the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
- Founded
- 1984
- CEO
- Mr. Erez Israeli
- Employees
- 27,527
- Headquarters
- Hyderabad, Telangana, India
- Fiscal year end
- 03-31
- Website
- drreddys.com
Company profile
- Exchange
- US
- Symbol
- RDY
- Market-cap rank
- #1451
- Listing date
- 1970-01-01
- Market cap
- 10.22B
- Float cap
- 7.36B
- Shares out
- 832.99M
- Float shares
- 599.98M
Sectors & themes
Quote time 2026-10-08 06:46:48 · For reference only, not investment advice and not tailored to your situation.